Form 4: AnaptysBio CFO Dennis Mulroy Reports Stock Transactions

AnaptysBio's Chief Financial Officer, Dennis Mulroy, has reported multiple transactions involving the company's stock, including the vesting of restricted stock units and the acquisition of shares through the employee stock purchase plan.

Summary

• Dennis Mulroy, the Chief Financial Officer of AnaptysBio, has filed a Form 4 detailing several transactions.
• On January 3, 2025, 8,293 restricted stock units (RSUs) vested, resulting in the acquisition of 8,293 shares of common stock.
• Additionally, 981 shares were acquired through the company's Employee Stock Purchase Plan (ESPP).
• To cover tax obligations related to the vesting of RSUs, 3,407 shares were withheld by the company at a price of $14.6 per share.
• On January 6, 2025, another 5,245 RSUs vested, resulting in the acquisition of 5,245 shares.
• A further 2,054 shares were withheld to cover taxes at a price of $15.3 per share.
• On January 7, 2025, 26,800 RSUs were granted, vesting over time, and 76,400 stock options were granted, also vesting over time.

Sentiment

Score: 7

Explanation: The document reflects routine insider transactions related to compensation. It is neither overly positive nor negative, but indicates standard practices.

Positives

• The vesting of RSUs and acquisition of shares through the ESPP indicate a positive compensation structure for the CFO.
• The grant of new RSUs and stock options suggests continued alignment of management's interests with shareholders.

Negatives

• The withholding of shares to cover tax obligations reduces the net gain for the CFO from the vesting of RSUs.

Risks

• The vesting of a large number of RSUs and stock options could potentially dilute the value of existing shares if not managed carefully.
• The CFO's transactions are subject to market fluctuations and could impact the value of his holdings.

Future Outlook

The document does not contain any specific forward-looking statements or guidance, but it does detail the vesting schedule for the RSUs and stock options.

Industry Context

This filing is a routine disclosure of insider transactions, which is common in the biotechnology industry. It provides transparency into the compensation and holdings of key executives.

Comparison to Industry Standards

• The vesting schedules for RSUs and stock options are typical for executive compensation in the biotech industry.
• Companies like Regeneron and Biogen also use similar equity-based compensation plans for their executives.
• The ESPP participation is a common benefit offered to employees in many publicly traded companies.

Stakeholder Impact

• The transactions may have a minor impact on shareholders due to potential dilution from the vesting of RSUs and stock options.
• Employees may be positively impacted by the ESPP and equity-based compensation.

Key Dates

Keywords

AnaptysBio, Form 4, Dennis Mulroy, Restricted Stock Units, Stock Options, Employee Stock Purchase Plan, Insider Trading, Share Acquisition, Vesting, Tax Withholding